ClinicalTrials.gg
CompletedNCT02087579Updated Oct 29, 2015

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

A Phase 1 interventional study of Aripiprazole, oral formulation and Olanzapine, oral formulation in Psychotic Disorders, Schizophrenia and Bipolar Disorder, sponsored by Janssen Research & Development, LLC. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-10-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
305
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing paliperidone in Psychotic Disorders — 1 open to participants now, 1 under way, none of them phase 3. paliperidone · Psychotic Disorders.

Enrollment
8th of 22
305 · median 189
Started
2014
the only one that year
Phase 1
6 of 22
none open now
Registered
13th of 22
by date
Lead sponsor
4 of 22
Janssen Research & Development, LLC

Among the 22 studies testing paliperidone in Psychotic Disorders, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 1, and was the 13th registered.

Psychotic Disorders

1,589 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

1 of the 22 studies testing paliperidone in Psychotic Disorders is open now. Recruiting first, the newest first:

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing paliperidone in Psychotic Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after dosing. In addition, comparison of capillary drug concentrations vs. venous drug concentrations will be performed for aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and their relevant metabolites.

Read the detailed description

This is an open-label (physicians and participants know the identity of the assigned treatment), parallel-group, multiple-dose, multicenter study to assess pharmacokinetics (what the body does to the medication) of five antipsychotics (APS) drugs: aripiprazole, olanzapine, paliperidone, quetiapine and risperidone in psychiatric participants who are receiving stable doses of these drugs for the treatment of their disease.

Pharmacokinetics data will be generated from venous and fingerstick-based capillary plasma concentrations of the drugs and their metabolites. The total number of enrolled participants in this study will be at least 265. Seventy-five participants will be enrolled for the aripiprazole, olanzapine and quetiapine cohorts (groups) each, and 20 participants will be enrolled for the paliperidone and risperidone cohorts each. In aripiprazole, olanzapine and quetiapine cohorts there will be two subgroups. Subgroup one, 20 participants for fingerstick capillary + venous blood sampling and subgroup two, 55 participants for only venous sampling. Paliperidone and risperidone cohorts will be subjected only to capillary + venous blood sampling.

The study will consist of a screening phase (within 21 days before Day 1) followed by a 3-day observation phase (Day 1 to Day 3). Participants will be admitted to the study center in the evening of Day -1 and will remain in the study center until discharged on Day 3 after completion of the last study-related procedure. During the observation phase, the administration of the prior antipsychotic medication will continue at a participant's usual dose and dosing schedule, under direct observation of the study staff. There will be no modification of the participant's medication during the study. Safety will be evaluated throughout the study and a mandatory pharmacogenomic blood sample will be collected for analysis of genes that may influence exposure of the APS studied.

03

Conditions studied

  • Psychotic Disorders
  • Schizophrenia
  • Bipolar Disorder
  • Depressive Disorder

Keywords

  • Psychotic Disorders
  • Schizophrenia
  • Bipolar Disorder
  • Depressive Disorder
  • Antipsychotics
  • Aripiprazole
  • Olanzapine
  • Paliperidone
  • Quetiapine
  • Risperidone
  • Capillary Concentration
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be clinically stable as per the investigator's judgment (no suicidal behavior or current significant suicidal judgment based on C-SSRS rating scale)
  • No hospitalization for exacerbation of psychiatric symptoms during 3 months before screening
  • Receiving treatment with aripiprazole, olanzapine, paliperidone, quetiapine or risperidone, or their combination before the study
  • Must have between 17 and 40 kg/m2 (inclusive), and body weight not less than 47 kg
  • Except for the indication for which the antipsychotic treatment is given, generally healthy with no or unstable medical problems
  • Must be able to give

Exclusion criteria

Exclusion Criteria:

  • abnormal physical examination, vital signs or 12-lead at screening as determined by the investigator
  • Administering of strong inhibitors or inducers of , CYP2D6 enzymes, like fluoxetine
  • History of or current clinically significant (particularly unstable) medical illness other than the indication
  • Donated blood or blood products or had substantial loss of blood (more than 450 mL) within 3 months before Day -1
  • Lack of 6 suitable puncture sites for capillary blood draws
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    Cohort A: Aripiprazole

    Administration of oral formulation will continue at a participant's usual dose and dosing schedule.

    Drug: Aripiprazole, oral formulation

  • Experimental
    Cohort B: Olanzapine

    Administration of oral formulation will continue at a participant's usual dose and dosing schedule.

    Drug: Olanzapine, oral formulation

  • Experimental
    Cohort C: Paliperidone

    Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.

    Drug: Paliperidone, oral formulation · Drug: Paliperidone, LAI

  • Experimental
    Cohort D: Quetiapine

    Administration of oral formulation will continue at a participant's usual dose and dosing schedule.

    Drug: Quetiapine, oral formulation

  • Experimental
    Cohort E: Risperidone

    Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.

    Drug: Risperidone, oral formulation · Drug: Risperidone, LAI

Interventions

  • DrugAripiprazole, oral formulation

    Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.

  • DrugOlanzapine, oral formulation

    Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.

  • Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

    Also known as: INVEGA®

  • Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.

    Also known as: INVEGA®

  • DrugQuetiapine, oral formulation

    Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

  • Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.

    Also known as: RISPERDAL®

  • Risperidone LAI injections will be administered will be administered per the locally approved label indications.

    Also known as: RISPERDAL®

06

What researchers measure

Primary outcomes

  1. Aripiprazole concentration in venous and capillary plasma

    Venous blood samples will be collected at 8 scheduled time points after dosing and compared to fingerstick-based capillary blood samples collected at 6 scheduled time points after dosing.

    Time frame: 14 time points over 3 days postdose

  2. Paliperidone concentration in venous and capillary plasma

    Time frame: 14 time points over 3 days postdose

  3. Olanzapine concentration in venous and capillary plasma

    Time frame: 14 time points over 3 days postdose

  4. Quetiapine concentration in venous and capillary plasma

    Time frame: 14 time points over 3 days postdose

  5. Risperidone concentration in venous and capillary plasma

    Time frame: 14 time points over 3 days postdose

Secondary outcomes

  1. Number of participants with an adverse event as a measure of safety

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days

07

Study locations

24 sites
  • Garden Grove, California, United States
  • Kissimmee, Florida, United States
  • Atlanta, Georgia, United States
  • Hoffman Estates, Illinois, United States
  • Cedarhurst, New York, United States
  • Austin, Texas, United States
  • Banfield, Argentina
  • Ciudad Autónoma De Buenos Aires, Argentina
  • Cordoba, Argentina
  • La Plata, Argentina
  • Aalst, Belgium
  • Antwerpen, Belgium
  • Brussel, Belgium
  • Kortenberg, Belgium
  • Rio De Janeiro, Brazil
  • Valinhos, Brazil
  • Bourgas, Bulgaria
  • Berlin, Germany
  • Hamburg, Germany
  • Luebeck, Germany
  • Badajoz, Spain
  • Barcelona, Spain
  • Torrevieja, Spain
  • Zamora, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2014
First posted
Mar 14, 2014
Start
Feb 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Last update
Oct 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02087579
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
Feb 2014
Primary completion
Oct 2014
Completion
Dec 2014
Last update
Oct 29, 2015

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paliperidone · Risperidone

Start the discussion